Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

NATH BIO-GENES (INDIA) LTD.

NSE : NATHBIOGENBSE : 537291ISIN CODE : INE448G01010Industry : AgricultureHouse : Private

BSE157.00-5 (-3.09 %)

PREV CLOSE ( ) 162.00

OPEN PRICE ( ) 159.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 2787

TODAY'S LOW / HIGH ( )156.00 164.35

52 WK LOW / HIGH ( )141.1 264.5

NSE157.79-4.24 (-2.62 %)

PREV CLOSE( ) 162.03

OPEN PRICE ( ) 162.93

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 34805

TODAY'S LOW / HIGH( ) 155.25 163.58

52 WK LOW / HIGH ( )137.55 264.31

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2013

Mar 2012

Operational & Financial Ratios

Earnings Per Share (Rs)

20.85

18.43

-35.46

7.34

5.75

CEPS(Rs)

22.56

20.01

-33.84

10.16

8.69

DPS(Rs)

2.00

0.00

Book NAV/Share(Rs)

320.94

301.61

285.16

35.91

28.57

Tax Rate(%)

4.68

3.19

-6.23

4.48

-1.38

Margin Ratios

Core EBITDA Margin(%)

15.02

16.25

13.37

14.45

11.84

EBIT Margin(%)

15.26

15.44

-18.96

11.60

8.78

Pre Tax Margin(%)

12.50

12.00

-22.79

8.93

7.32

PAT Margin (%)

11.91

11.62

-24.21

8.53

7.42

Cash Profit Margin (%)

12.89

12.62

-23.10

11.80

11.22

Performance Ratios

ROA(%)

4.74

4.57

-15.03

8.50

7.73

ROE(%)

6.70

6.28

-22.48

22.76

20.12

ROCE(%)

7.26

7.09

-14.84

23.88

19.09

Asset Turnover(x)

0.40

0.39

0.62

1.00

1.04

Sales/Fixed Asset(x)

1.22

1.12

1.62

2.08

2.22

Working Capital/Sales(x)

1.08

0.99

1.02

6.37

5.12

Efficiency Ratios

Fixed Capital/Sales(x)

0.82

0.89

0.62

0.48

0.45

Receivable days

105.14

110.74

69.85

44.32

36.68

Inventory Days

240.40

259.30

195.06

189.43

193.69

Payable days

-1457.17

744.29

1503.38

-4219.16

1576.65

Valuation Parameters

PER(x)

8.33

7.69

0.00

PCE(x)

7.70

7.08

-6.31

0.00

Price/Book(x)

0.54

0.47

0.75

0.00

Yield(%)

1.15

1.41

0.94

EV/Net Sales(x)

1.09

1.12

1.78

0.24

0.19

EV/Core EBITDA(x)

7.18

6.79

12.65

1.60

1.54

EV/EBIT(x)

7.15

7.23

-9.36

2.05

2.20

EV/CE(x)

0.50

0.78

0.21

0.20

M Cap / Sales

0.99

0.89

1.46

0.00

Growth Ratio

Net Sales Growth(%)

10.37

8.26

102.15

11.13

0.00

Core EBITDA Growth(%)

2.11

26.77

90.81

31.43

0.00

EBIT Growth(%)

9.13

188.13

-430.58

46.76

0.00

PAT Growth(%)

13.16

151.96

-673.70

27.66

0.00

EPS Growth(%)

13.11

151.98

-583.10

27.66

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.18

0.17

0.33

0.25

Current Ratio(x)

2.18

2.40

2.41

1.22

1.34

Quick Ratio(x)

1.30

1.44

1.27

0.43

0.42

Interest Cover(x)

5.52

4.49

-4.96

4.35

6.02

Total Debt/Mcap(x)

0.33

0.39

0.23